Clinical Trial Update: Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients [Phase 2]

View source ↗

Summary

This is a completed Phase 2 study evaluating apatinib in patients with metastatic triple-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Apatinib (apatinib)

Snippet

Sponsor: Fudan University | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED